Second Chance for Moms Act of 2025 This bill requires labeling of the drug mifepristone to include certain information about the hormone progesterone and establishes a related telephone hotline. (Mifepristone is a drug that is approved to end pregnancies through 10 weeks gestation when used in conjunction with the drug misoprostol. The procedure is often referred to as medication abortion or the abortion pill.)
Referred to the House Committee on Energy and Commerce.
Bill introduced
Lobbying filed by STUDENTS FOR LIFE ACTION
Lobbying filed by STUDENTS FOR LIFE ACTION
Referred to the House Committee on Energy and Commerce.
| Registrant | Client | Amount | Filed | Period | Issues |
|---|---|---|---|---|---|
| STUDENTS FOR LIFE ACTION | STUDENTS FOR LIFE ACTION | Undisclosed | Aug 4, 2025 | 2025Q2 | GOVFAM |
| STUDENTS FOR LIFE ACTION | STUDENTS FOR LIFE ACTION | Undisclosed | Apr 22, 2025 | 2025Q1 | GOVFAM |
The lobbying table lists Senate LDA quarterly reports (LD-2) that cite this bill by number and cover a quarter of the 119th Congress. An LD-2 names a bill as “H.R. 1234” with no Congress, so a report on another Congress, which can only concern a different bill with the same number, is left out, even when it was filed after this Congress began. The amount is what the registrant reported for the whole filing, across every issue on it, not spending on this bill. Official actions and the bill summary come from Congress.gov, and votes from the roll-call record. This page no longer pairs the bill with members' stock trades: matching lobbying clients to traded companies by name, and trades to a bill by date, is not something the records establish.